Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced the appointment of David Uffer as Vice President of Advanced Technologies and Director of Plasma sales and marketing. Mr. Uffer comes to Bovie with 18 years experience in the medical products industry. He has been extensively involved in several new product introductions including: supervising and staffing sales representatives, developing worldwide marketing plans, creating customer training modules, accessing clinical trials and establishing strategic partnerships.

Andrew Makrides, president of Bovie, stated, “David is a welcome addition to Bovie’s management team. His experience with new product launches should accelerate J-Plasma’s entree into the marketplace.”

Management believes that J-Plasma has potential in several surgical specialties including dermatology and plastic surgery. In addition, we are encouraged by the feedback from our participation and presentation at the International Conference on Plasma Medicine in March 2009. The conference, technical in scope, provided the Company an excellent opportunity to assess the current status of plasma medicine.

As previously reported on March 3, 2009, Bovie submitted a 510(K) pre-market notification application to the U.S. Food and Drug Administration (FDA).

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.

This document may contain some forward looking statements, particularly regarding operational prospects in 2009 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.

Investors:
Buttonwood Advisory Group, Inc.
John Aneralla, 1-800-940-9087